Clinical trials: Castrate-resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
This phase II trial tests how well abiraterone acetate/niraparib (CJNJ-67652000 [niraparib/abiraterone acetate fixed-dose combination]) and prednisone works in treating patients with castration-resistant prostate cancer that has…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05689021
- Testing
- Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Adenocarcinoma
A Long Term Safety Study With Atrasentan
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
- Trial name
- NCT00127478
- Testing
- Atrasentan
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 166 people
- Sponsor
- Abbott
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of PI3Kbeta inhibitor AZD8186 when given together with docetaxel in treating patients with solid tumors with PTEN or PIK3CB mutations that have spread to other places in…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03218826
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
The purpose of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-cancer activity of GI-102 in combination with pasritamig in adult men with metastatic castration-resistant prostate cancer (mCRPC)…
- Trial name
- NCT07871435
- Testing
- GI-102, Pasritamig
- Where
- 6 sites in United States, South Korea
- Volunteers
- 107 people
- Sponsor
- GI Innovation, Inc.
Prostate Cancer
Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help carboplatin kill more cancer cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00017576
- Testing
- calcitriol, carboplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Castration-Resistant Prostatic Cancer
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life…
- Trial name
- PARABO (NCT02398526)
- Testing
- Radium-223 dichloride, (Xofigo, BAY88-8223)
- Where
- Germany
- Volunteers
- 363 people
- Sponsor
- Bayer
Neoplasms, Prostate
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway…
- Trial name
- NCT07802704
- Testing
- Risvutatug rezetecan (Ris-Rez), Enzalutamide, Abiraterone
- Where
- 6 sites in Australia, Canada and 2 more
- Volunteers
- 684 people
- Sponsor
- GlaxoSmithKline
Metastatic Prostate Cancer
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants…
- Trial name
- IPATential150 (NCT03072238)
- Testing
- Ipatasertib, Abiraterone, Prednisone/Prednisolone
- Where
- 176 sites in United States, Australia and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Hoffmann-La Roche
Solid Malignancies, Metastatic Castrate-resistant Prostate Cancer
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
The main purpose of this study is to learn more about the safety of an investigational drug, axitinib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for…
- Trial name
- NCT01540526
- Testing
- axitinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer
The primary objective of this study is to assess disease response to Doxil in patients with hormone refractory prostate cancer with or without dexamethasone pre-treatment.
- Trial name
- NCT00176293
- Testing
- dexamethasone, doxorubicin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Kentucky
Prostate Cancer
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005847
- Testing
- recombinant interferon alfa, estramustine phosphate sodium, isotretinoin
- Where
- 19 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Prostate Cancer
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body.
- Trial name
- DAROL (NCT04122976)
- Testing
- Darolutamide(Nubeqa, BAY1841788)
- Where
- 40 sites in United States, Argentina and 15 more
- Volunteers
- 805 people
- Sponsor
- Bayer
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
In this study, ASP5541 will be given to Chinese men with prostate cancer. It will be given together with prednisone and androgen deprivation therapy (ADT).
- Conditions
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
- Trial name
- NCT07339267
- Testing
- ASP5541, Prednisone
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment, and Lutetium 177Lu-prostate specific-membrane antigen…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06039371
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Washington
Prostatic Neoplasms
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate pharmacokinetics (PK) following a single dose and multiple dose treatment and the safety of apalutamide in Chinese participants with metastatic castration resistant prostate cancer (mCRPC)…
- Trial name
- NCT03523442
- Testing
- Apalutamide
- Where
- 4 sites in China
- Volunteers
- 19 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
Prostate Cancer Biobank
Carcinoma of the prostate is the second most commonly diagnosed cancer and occurs predominantly in older men - almost two-thirds of those affected are over 65 years of age.
- Trial name
- NCT04024475
- Testing
- Observation
- Where
- 12 sites in Switzerland
- Volunteers
- 1,323 people
- Sponsor
- Swiss Cancer Institute
Prostate Cancer
Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
This clinical study will evaluate the role of combination therapy of Provenge followed by docetaxel for patients with metastatic castration-resistant prostate cancer (CRPC, (prostate cancer that is resistant to medical or…
- Trial name
- NCT02793219
- Testing
- Sipuleucel-T, Docetaxel
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Prostate Cancer
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
Background: Enzalutamide is given to treat metastatic prostate cancer. But it takes 4 pills to deliver the effective dose. This can be difficult for people already taking multiple drugs.
- Trial name
- NCT03478904
- Testing
- Enzalutamide Liquid, Enzalutamide Capsule
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Abiraterone Acetate for Castrate Resistant Prostate Cancer
This research study is a Pilot clinical trial. Pilot clinical trials often examine new tests (such as laboratory or radiology tests) in patients who receive either standard cancer treatments or new treatments that have been…
- Trial name
- NCT01961843
- Testing
- Abiraterone, Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Metastatic Castration Resistant Prostate Cancer
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
The purpose of this study is to provide real world data on treatment with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients.
- Trial name
- NCT03328364
- Testing
- enzalutamide, docetaxel
- Where
- Sweden
- Volunteers
- 211 people
- Sponsor
- Astellas Pharma a/s
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.